223 related articles for article (PubMed ID: 32480317)
1. Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders.
Fiorucci S; Baldoni M; Ricci P; Zampella A; Distrutti E; Biagioli M
Curr Opin Pharmacol; 2020 Aug; 53():45-54. PubMed ID: 32480317
[TBL] [Abstract][Full Text] [Related]
2. Bile Acids Activated Receptors Regulate Innate Immunity.
Fiorucci S; Biagioli M; Zampella A; Distrutti E
Front Immunol; 2018; 9():1853. PubMed ID: 30150987
[TBL] [Abstract][Full Text] [Related]
3. Bile Acid Signaling in Inflammatory Bowel Diseases.
Fiorucci S; Carino A; Baldoni M; Santucci L; Costanzi E; Graziosi L; Distrutti E; Biagioli M
Dig Dis Sci; 2021 Mar; 66(3):674-693. PubMed ID: 33289902
[TBL] [Abstract][Full Text] [Related]
4. Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders.
Fiorucci S; Sepe V; Biagioli M; Fiorillo B; Rapacciuolo P; Distrutti E; Zampella A
Biochem Pharmacol; 2023 Oct; 216():115776. PubMed ID: 37659739
[TBL] [Abstract][Full Text] [Related]
5. Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders.
Fiorucci S; Distrutti E
Trends Mol Med; 2015 Nov; 21(11):702-714. PubMed ID: 26481828
[TBL] [Abstract][Full Text] [Related]
6. Signaling from Intestine to the Host: How Bile Acids Regulate Intestinal and Liver Immunity.
Biagioli M; Carino A
Handb Exp Pharmacol; 2019; 256():95-108. PubMed ID: 31119464
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory functions of FXR.
Fiorucci S; Zampella A; Ricci P; Distrutti E; Biagioli M
Mol Cell Endocrinol; 2022 Jul; 551():111650. PubMed ID: 35472625
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling.
Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Morretta E; Monti MC; Distrutti E; Fiorucci S
FASEB J; 2022 Jan; 36(1):e22060. PubMed ID: 34862975
[TBL] [Abstract][Full Text] [Related]
9. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
[TBL] [Abstract][Full Text] [Related]
10. Bile Acids Activated Receptors in Inflammatory Bowel Disease.
Biagioli M; Marchianò S; Carino A; Di Giorgio C; Santucci L; Distrutti E; Fiorucci S
Cells; 2021 May; 10(6):. PubMed ID: 34064187
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.
Carino A; Marchianò S; Biagioli M; Fiorucci C; Zampella A; Monti MC; Morretta E; Bordoni M; Di Giorgio C; Roselli R; Ricci P; Distrutti E; Fiorucci S
Nutrients; 2019 May; 11(5):. PubMed ID: 31117231
[TBL] [Abstract][Full Text] [Related]
12. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
13. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
De Marino S; Festa C; Sepe V; Zampella A
Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
[TBL] [Abstract][Full Text] [Related]
14. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.
Finamore C; Festa C; Renga B; Sepe V; Carino A; Masullo D; Biagioli M; Marchianò S; Capolupo A; Monti MC; Fiorucci S; Zampella A
Sci Rep; 2016 Jul; 6():29320. PubMed ID: 27381677
[TBL] [Abstract][Full Text] [Related]
15. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
Chiang JYL; Ferrell JM
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
[TBL] [Abstract][Full Text] [Related]
16. Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
Marchianò S; Biagioli M; Bordoni M; Morretta E; Di Giorgio C; Vellecco V; Roselli R; Bellini R; Massa C; Cari L; Urbani G; Ricci P; Monti MC; Giordano A; Brancaleone V; Bucci M; Zampella A; Distrutti E; Cieri E; Cirino G; Fiorucci S
J Am Heart Assoc; 2023 Dec; 12(23):e031241. PubMed ID: 37996988
[TBL] [Abstract][Full Text] [Related]
17. Bile acid receptors and the kidney.
Herman-Edelstein M; Weinstein T; Levi M
Curr Opin Nephrol Hypertens; 2018 Jan; 27(1):56-62. PubMed ID: 29045336
[TBL] [Abstract][Full Text] [Related]
18. Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators.
Fiorucci S; Zampella A; Cirino G; Bucci M; Distrutti E
Am J Physiol Heart Circ Physiol; 2017 Jan; 312(1):H21-H32. PubMed ID: 27765751
[TBL] [Abstract][Full Text] [Related]
19. Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties.
Finamore C; Baronissi G; Marchianò S; Di Leva FS; Carino A; Monti MC; Limongelli V; Zampella A; Fiorucci S; Sepe V
Molecules; 2019 Mar; 24(6):. PubMed ID: 30884797
[TBL] [Abstract][Full Text] [Related]
20. The Pharmacology of Bile Acids and Their Receptors.
Fiorucci S; Distrutti E
Handb Exp Pharmacol; 2019; 256():3-18. PubMed ID: 31201555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
